Related references
Note: Only part of the references are listed.PTEN loss correlates with T cell exclusion across human cancers
Ziying Lin et al.
BMC CANCER (2021)
Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer
Anita K. Mehta et al.
NATURE CANCER (2021)
The repertoire of mutational signatures in human cancer
Ludmil B. Alexandrov et al.
NATURE (2020)
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
Anniina Farkkila et al.
NATURE COMMUNICATIONS (2020)
Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium
Filipe Correia Martins et al.
BRITISH JOURNAL OF CANCER (2020)
Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer
Adam A. Kraya et al.
CLINICAL CANCER RESEARCH (2019)
Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer Phase 1b Results From the JAVELIN Solid Tumor Trial
Mary L. Disis et al.
JAMA ONCOLOGY (2019)
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study
U. A. Matulonis et al.
ANNALS OF ONCOLOGY (2019)
Association of BRCA1-and BRCA2-deficiency with mutation burden, expression of PD-L1/ PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer
Wei Xiong Wen et al.
PLOS ONE (2019)
Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors
Denarda Dangaj et al.
CANCER CELL (2019)
Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma
Panagiotis A. Konstantinopoulos et al.
JAMA ONCOLOGY (2019)
Genomic and Functional Approaches to Understanding Cancer Aneuploidy
Alison M. Taylor et al.
CANCER CELL (2018)
Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer
Allen W. Zhang et al.
CELL (2018)
An Overview of Immune Checkpoint Inhibitors in Gynecologic Cancers
Tara Castellano et al.
CLINICAL THERAPEUTICS (2018)
Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy
Jinyang Li et al.
IMMUNITY (2018)
Loss of PTEN-assisted G2/M checkpoint impedes homologous recombination repair and enhances radio-curability and PARP inhibitor treatment response in prostate cancer
W. Y. Mansour et al.
SCIENTIFIC REPORTS (2018)
The Multifaceted Role of Chromosomal Instability in Cancer and Its Microenvironment
Samuel F. Bakhoum et al.
CELL (2018)
Targeting Resident Memory T Cells for Cancer Immunotherapy
Charlotte Blanc et al.
FRONTIERS IN IMMUNOLOGY (2018)
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
Livnat Jerby-Arnon et al.
CELL (2018)
Emerging Role and Future Directions of Immunotherapy in Advanced Ovarian Cancer
Thinle Chodon et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2018)
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
K. Moore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer
David Balli et al.
CLINICAL CANCER RESEARCH (2017)
ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells
Stephanie A. Yazinski et al.
GENES & DEVELOPMENT (2017)
Pan-cancer analysis distinguishes transcriptional changes of aneuploidy from proliferation
Christopher Buccitelli et al.
GENOME RESEARCH (2017)
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2
Amit M. Oza et al.
GYNECOLOGIC ONCOLOGY (2017)
Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma
Suzanne George et al.
IMMUNITY (2017)
PARP inhibitors: Synthetic lethality in the clinic
Christopher J. Lord et al.
SCIENCE (2017)
Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy
Teresa Davoli et al.
SCIENCE (2017)
Enhanced anti-tumour immunity requires the interplay between resident and circulating memory CD8+ T cells
Michel Enamorado et al.
NATURE COMMUNICATIONS (2017)
BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers
Kara N. Maxwell et al.
NATURE COMMUNICATIONS (2017)
IFN-β induces greater antiproliferative and proapoptotic effects and increased p53 signaling compared with IFN-α in PBMCs of Adult T-cell Leukemia/Lymphoma patients
T. Dierckx et al.
BLOOD CANCER JOURNAL (2017)
Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Olga Kondrashova et al.
CANCER DISCOVERY (2017)
Crosstalk between Regulatory T Cells and Tumor-Associated Dendritic Cells Negates Anti-tumor Immunity in Pancreatic Cancer
Jung-Eun Jang et al.
CELL REPORTS (2017)
A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors
Rebecca Kristeleit et al.
CLINICAL CANCER RESEARCH (2017)
Local Activation of p53 in the Tumor Microenvironment Overcomes Immune Suppression and Enhances Antitumor Immunity
Gang Guo et al.
CANCER RESEARCH (2017)
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
Weiyi Peng et al.
CANCER DISCOVERY (2016)
Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma
Silvia Darb-Esfahani et al.
ONCOTARGET (2016)
Complex heatmaps reveal patterns and correlations in multidimensional genomic data
Zuguang Gu et al.
BIOINFORMATICS (2016)
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
Melinda L. Telli et al.
CLINICAL CANCER RESEARCH (2016)
Evaluation of rucaparib and companionydiagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy
Zachary B. Jenner et al.
FUTURE ONCOLOGY (2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
Kyle C. Strickland et al.
ONCOTARGET (2016)
A novel TP53-KPNA3 translocation defines a de novo treatment-resistant clone in osteosarcoma
Kenneth S. Chen et al.
COLD SPRING HARBOR MOLECULAR CASE STUDIES (2016)
The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1-/- murine model of ovarian cancer
Jing Huang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2015)
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
Michael S. Rooney et al.
CELL (2015)
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Bella Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Whole-genome characterization of chemoresistant ovarian cancer
Ann-Marie Patch et al.
NATURE (2015)
limma powers differential expression analyses for RNA-sequencing and microarray studies
Matthew E. Ritchie et al.
NUCLEIC ACIDS RESEARCH (2015)
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Panagiotis A. Konstantinopoulos et al.
CANCER DISCOVERY (2015)
CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
Tomoe Higuchi et al.
CANCER IMMUNOLOGY RESEARCH (2015)
PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer
John R. Webb et al.
CANCER IMMUNOLOGY RESEARCH (2015)
The Molecular Signatures Database Hallmark Gene Set Collection
Arthur Liberzon et al.
CELL SYSTEMS (2015)
Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data
F. Favero et al.
ANNALS OF ONCOLOGY (2015)
Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations
Yaser R. Hussein et al.
MODERN PATHOLOGY (2015)
The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
Nicolas J. Llosa et al.
CANCER DISCOVERY (2015)
OptiType: precision HLA typing from next-generation sequencing data
Andras Szolek et al.
BIOINFORMATICS (2014)
Tumor-Infiltrating Lymphocytes Expressing the Tissue Resident Memory Marker CD103 Are Associated with Increased Survival in High-Grade Serous Ovarian Cancer
John R. Webb et al.
CLINICAL CANCER RESEARCH (2014)
Pten Null Prostate Epithelium Promotes Localized Myeloid-Derived Suppressor Cell Expansion and Immune Suppression during Tumor Initiation and Progression
Alejandro J. Garcia et al.
MOLECULAR AND CELLULAR BIOLOGY (2014)
Enhancing Chemotherapy Efficacy in Pten-Deficient Prostate Tumors by Activating the Senescence-Associated Antitumor Immunity
Alberto Toso et al.
CELL REPORTS (2014)
Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers
Johnathan A. Watkins et al.
BREAST CANCER RESEARCH (2014)
Combined image and genomic analysis of high-grade serous ovarian cancer reveals PTEN loss as a common driver event and prognostic classifier
Filipe C. Martins et al.
GENOME BIOLOGY (2014)
GSVA: gene set variation analysis for microarray and RNA-Seq data
Sonja Haenzelmann et al.
BMC BIOINFORMATICS (2013)
viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia
El-ad David Amir et al.
NATURE BIOTECHNOLOGY (2013)
Mechanisms of resistance to therapies targeting BRCA-mutant cancers
Christopher J. Lord et al.
NATURE MEDICINE (2013)
MATH, a novel measure of intratumor genetic heterogeneity, is high in poor-outcome classes of head and neck squamous cell carcinoma
Edmund A. Mroz et al.
ORAL ONCOLOGY (2013)
Nuclear PTEN Controls DNA Repair and Sensitivity to Genotoxic Stress
C. Bassi et al.
SCIENCE (2013)
Inferring tumour purity and stromal and immune cell admixture from expression data
Kosuke Yoshihara et al.
NATURE COMMUNICATIONS (2013)
Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1-Mutated Mouse Mammary Tumors
Janneke E. Jaspers et al.
CANCER DISCOVERY (2013)
Identification of NCF2/p67phox as a novel p53 target gene
Dafne Italiano et al.
CELL CYCLE (2012)
ENIGMA-Evidence-Based Network for the Interpretation of Germline Mutant Alleles: An International Initiative to Evaluate Risk and Clinical Significance Associated with Sequence Variation in BRCA1 and BRCA2 Genes
Amanda B. Spurdle et al.
HUMAN MUTATION (2012)
NetMHCcons: a consensus method for the major histocompatibility complex class I predictions
Edita Karosiene et al.
IMMUNOGENETICS (2012)
Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma
Robert A. Soslow et al.
MODERN PATHOLOGY (2012)
Cancer treatment according to BRCA1 and BRCA2 mutations
Kara N. Maxwell et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
CD8+Foxp3+ tumor infiltrating lymphocytes accumulate in the context of an effective anti-tumor response
Dung T. Le et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
Barbara Norquist et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
M. William Audeh et al.
LANCET (2010)
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
Junko Matsuzaki et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss
Blaise Clarke et al.
MODERN PATHOLOGY (2009)
PKR, a p53 target gene, plays a crucial role in the tumor-suppressor function of p53
Cheol-Hee Yoon et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities
Joshua Z. Press et al.
BMC CANCER (2008)
BRCA1 promoter methylation predicts adverse ovarian cancer prognosis
Jing Wang Chiang et al.
GYNECOLOGIC ONCOLOGY (2006)
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
E Sato et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer
L Zhang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Share Paper
